Clinical data
| No. of patients | 905 |
| Median age, y (range) | 30 (1-66) |
| Donor-recipient sex match, no. of patients (%) | |
| Female to male | 249 (28) |
| Others | 656 (72) |
| Median donor age, y (range) | 31 (2-77) |
| Stem cell source: bone marrow, no. of patients (%) | 905 (100) |
| Donor type, no. of patients (%) | |
| HLA-identical sibling | 735 (81) |
| Mismatched related donor | 35 (4) |
| Matched unrelated donor | 135 (15) |
| Disease, no. of patients (%) | |
| SAA | 94 (10) |
| CML | 298 (33) |
| AML | 234 (26) |
| ALL | 163 (18) |
| MDS | 61 (7) |
| LPDs | 55 (6) |
| Disease state, no. of patients (%)* | |
| First CR/CP | 448 (55) |
| TBI, no. of patients (%) | |
| Yes | 656 (72) |
| No | 249 (28) |
| Interval between diagnosis and BMT, d (range) | 326 (22-6240) |
| Median follow-up for deceased patients, d (range) | 124 (1-6533) |
| Median follow-up for surviving patients, d (range) | 2510 (88-9094) |
| No. of patients | 905 |
| Median age, y (range) | 30 (1-66) |
| Donor-recipient sex match, no. of patients (%) | |
| Female to male | 249 (28) |
| Others | 656 (72) |
| Median donor age, y (range) | 31 (2-77) |
| Stem cell source: bone marrow, no. of patients (%) | 905 (100) |
| Donor type, no. of patients (%) | |
| HLA-identical sibling | 735 (81) |
| Mismatched related donor | 35 (4) |
| Matched unrelated donor | 135 (15) |
| Disease, no. of patients (%) | |
| SAA | 94 (10) |
| CML | 298 (33) |
| AML | 234 (26) |
| ALL | 163 (18) |
| MDS | 61 (7) |
| LPDs | 55 (6) |
| Disease state, no. of patients (%)* | |
| First CR/CP | 448 (55) |
| TBI, no. of patients (%) | |
| Yes | 656 (72) |
| No | 249 (28) |
| Interval between diagnosis and BMT, d (range) | 326 (22-6240) |
| Median follow-up for deceased patients, d (range) | 124 (1-6533) |
| Median follow-up for surviving patients, d (range) | 2510 (88-9094) |
SAA indicates severe aplastic anemia; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplasia; LPDs, lymphoproliferative disorders; CR, complete remission; CP, chronic phase; TBI, total body irradiation; and BMT, bone marrow transplantation.
The disease state is evaluated only in leukemia patients (n = 811).